NEXT with Michael Sonnenfeldt Returns for Season 2, Featuring Visionary Entrepreneurs Shaping What Comes Next

Announcing Season 2 of NEXT with Michael Sonnenfeldt. The biweekly podcast hosted by TIGER 21 Founder and Chairman Michael Sonnenfeldt, explores what comes after extraordinary success through candid conversations with some of the world’s most accomplished entrepreneurs and wealth creators. Michael Sonnenfeldt is an entrepreneur, investor, and philanthropist, best known as the founder of TIGER […]

GTCR Completes Sale of Worldpay to Global Payments

GTCR, a leading private equity firm, announced today that it has closed the previously announced sale of Worldpay (the “Company”), a global leader in merchant acquiring and payments processing, to Global Payments (NYSE: GPN) as part of a transformative three-way transaction. The sale of Worldpay represents one of the largest strategic sales in the history

Brookdale Reports December 2025 Occupancy

Strong month-end occupancy provides a solid entry point and momentum for 2026 Brookdale Senior Living Inc. (NYSE: BKD) reported today its occupancy for December 2025. Fourth Quarter and December 2025 Occupancy Observations — Fourth quarter occupancy results: — Consolidated weighted average occupancy of 82.5% represents a 70 basis point increase over the third quarter of

Osisko Metals Announces C$15 Million “Bought Deal” Flow-Through Share Financing

(TSX:OM), NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Jan. 12, 2026 (GLOBE NEWSWIRE) — Osisko Metals Incorporated (the “Company” or “Osisko Metals“) (TSX: OM; OTCQX: OMZNF; FRANKFURT: OB51) is pleased to announce that it has entered into an agreement with Canaccord Genuity Corp., as sole

ARTBIO Announces Dosing of Two Cohorts with AB001 in ARTISAN, a Phase 1 Alpha Radioligand Therapy Clinical Trial for Metastatic Castration Resistant Prostate Cancer

The ARTISAN trial is assessing the safety and anti-tumor activity of lead asset AB001 in patients with metastatic castration-resistant prostate cancer (mCRPC) Two cohorts, 177Lu-PSMA naïve patients and 177Lu-PSMA experienced patients, have been dosed in line with study protocol ARTBIO, Inc. (“ARTBIO”), a clinical-stage radiopharmaceutical company developing a new class of 212Pb alpha radioligand therapies

IN TWO WEEKS: Little Rock Students to Shine in School Choice Showcase

More than 500 students from across Arkansas will gather at the Robinson Center on Wednesday, Jan. 28 with a simple message: they love their schools and they are grateful for school choice. The event, which showcases the different K-12 education options in the Natural State, is timed to coincide with National School Choice Week. At

Corero Network Security Delivers Strong Full-Year 2025 Performance Driven by Global Customer Wins and Expanding Enterprise Adoption

Year-end update highlights 23% ARR growth, regional expansion, and competitive takeouts across telecom, data center, and enterprise markets Corero Network Security (AIM: CNS) (OTCQX: DDOSF), a recognized leader in DDoS protection and champion of adaptive, real-time service availability, today provided a year-end business update for full-year 2025, highlighting strong annual recurring revenue (ARR) growth, expanding

Doseology Engages McKinney Regulatory Science Advisors to Advance Innovative Oral Pouch Product Development through Science and Regulatory Expertise

Doseology Sciences Inc. (CSE: MOOD) (PINK: DOSEF) (FSE: VU70) (“Doseology” or the “Company”) a leader in biotechnology-driven consumer products, today announced a strategic partnership with McKinney Regulatory Science Advisors (“McKinney”), a premier FDA regulatory consulting firm specializing in nicotine and reduced-risk consumer products, to spearhead its regulatory submission strategy and solidify its commitment to scientific

CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Results and Business Update

Fourth quarter and Full-Year 2025 revenue are expected to be approximately $9.2 million and $37.0 million, respectively, with expected Q4 gross margins in the range of 73% to 75% DrugSorb®-ATR De Novo Pre-Submission M eeting scheduled with the FDA this month, with anticipated De Novo Application filing this quarter and regulatory decision in mid-2026 Results

Waystar Introduces Agentic AI to Advance Toward the Autonomous Revenue Cycle

Extends the impact of Waystar AltitudeAI, which has prevented $15.5 billion in denials in under one year Leverages a unique combination of proprietary data from more than 7.5 billion annual transactions and one in three U.S. hospital discharges Waystar (Nasdaq: WAY), a provider of leading healthcare payment software, today announced the introduction of agentic intelligence

Scroll to Top